Month-3 Immune Markers Linked to Rituximab Remission in PMN

Key Takeaways
- In a single-center cohort of patients with primary membranous nephropathy treated with rituximab, a majority attained partial or complete remission.
- Patients who achieved remission during follow-up had deeper B-cell depletion and lower SIRI at month 3 than nonresponders.
- Responders also had higher CD4+CD25+FoxP3+ T-cell levels and fewer intermediate monocytes at month 3.
- A combined-marker model showed apparent discrimination, which the investigators said requires multicenter validation.
Investigators prospectively followed a single-center prospective cohort of rituximab-treated patients with primary membranous nephropathy. The 35 patients received a standard two-dose rituximab regimen.
Flow cytometry assessed B-cell, T-cell, and monocyte compartments; investigators also measured the systemic inflammation response index (SIRI) and phospholipase A2 receptor antibody at baseline and months 3, 6, and 12. They compared month-3 measurements between patients who achieved partial or complete remission during follow-up and those who did not, rather than comparing randomized treatment arms.
Partial or complete remission occurred in 23 of 35 patients (65.7%), with a mean time to remission of 7.48 ± 2.4 months. At month 3, patients who achieved remission during follow-up had deeper B-cell depletion, higher CD4+CD25+FoxP3+ T-cell levels, fewer intermediate monocytes, and lower SIRI than nonresponders.
In multivariable analysis, total CD3−CD19+ B cells below 0.5% at month 3 were associated with greater odds of remission (odds ratio [OR] 5.8; 95% confidence interval [CI] 1.1–31.1).
Each 0.1-unit higher SIRI at month 3 was associated with lower odds of remission in the multivariable analysis (OR 0.44, 95% CI 0.22–0.91).
Combining the month-3 B-cell and SIRI measurements in a hypothesis-generating model yielded an apparent area under the curve (AUC) of 0.87. This describes discrimination within the cohort examined, not validated prediction for individual patients.
The small, single-center observational cohort limits how confidently the associations can be extended beyond the patients studied. The investigators called for multicenter validation of the candidate biomarkers; the model's apparent discrimination is not validated predictive performance.
The authors interpreted month-3 peripheral immune measurements as candidate markers of remission after rituximab in primary membranous nephropathy, pending multicenter validation.
Clinician Questions
Are partial and complete remission reported separately after rituximab for primary membranous nephropathy?
In rituximab-treated primary membranous nephropathy, the reported outcome combines partial and complete remission; separate results for each category and operational definitions are not provided in the available findings. The combined outcome therefore does not show which type of remission predominated.
Does month-3 immune profiling show that changing rituximab treatment improves remission in primary membranous nephropathy?
No. Among patients with primary membranous nephropathy receiving a standard two-dose rituximab regimen, investigators associated month-3 B-cell depletion and SIRI with later remission but did not evaluate biomarker-guided treatment changes. Those associations do not establish that adjusting rituximab treatment based on either marker improves outcomes.
This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.